

CLAIMS

What is claimed is:

5

1. A method of treatment, comprising:
 - a) providing:
 - i) a subject having a symptom of inflammatory bowel disease or short bowel syndrome,
 - 10 ii) a therapeutic composition comprising an angiotensin converting enzyme inhibitor, and;
 - b) administering said composition to said subject under conditions such that said symptom is reduced.

15

2. The method of Claim 1, wherein said subject is a mammal.

3. The method of Claim 2, wherein said mammal is a human.

20

4. The method of Claim 1, wherein the route of administration of said composition is selected from intravenously, orally, parenterally, topically, and rectally.

5. The method of Claim 1, wherein said composition further comprises a transdermal patch.

25

6. The method of Claim 1, wherein said symptom of inflammatory bowel disease is associated with diseases selected from the group consisting of Crohn's disease, irritable bowel syndrome, celiac disease, ulcerative colitis, stomach ulcers, diverticulitis, pouchitis, proctitis or chronic diarrhea.

30

7. The method of Claim 1, wherein said angiotensin converting enzyme inhibitor is selected from the group consisting of alacepril, benazepril (Lotensin), captopril (Capoten), cilazapril, ceranapril, delapril, enalapril (Vasotec), enalaprilat, fosinopril (Monopril),

fosinoprilat, imidapril, lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), perindoprilat, quinapril (Accupril), quinaprilat, ramipril (Altace), saralasin acetate, spirapril, temocapril,trandolapril (Mavik), Bioproject BP1.137, Chiesi CHF 1514, Fisons FPL-66564, idrapril, Marion Merrell Dow MDL-100240, and Servier S-5590.

5

8. A method of treatment comprising:

a) providing:

i) a subject at risk for inflammatory bowel disease or short bowel syndrome, and

10

ii) a composition comprising angiotensin converting enzyme inhibitors, and;

b) administering to said subject a therapeutically effective amount of said composition so as to prevent said subject from experiencing symptoms of inflammatory bowel disease.

15

9. The method of Claim 8, wherein said administration of said therapeutic composition delays the onset of symptoms of inflammatory bowel disease.

10. The method of Claim 8, wherein said subject at risk for inflammatory bowel disease is a human.

20

11. The method of Claim 10, wherein said human is selected from a child or adult, a person living in the United States, a person living in England, a person living in Northern Europe, a person of Jewish descent, a person living in a developing nation, a person with family members who suffer from inflammatory bowel disease or a person determined to carry an inflammatory bowel disease risk gene.

25

12. The method of Claim 8, wherein the route of administration of said composition is selected from intravenously, orally, parenterally, topically, and rectally.

30

13. The method of Claim 8, wherein said composition further comprises a

transdermal patch.

14. The method of Claim 8, wherein said subject at risk for inflammatory bowel disease is at risk for developing Crohn's disease, irritable bowel syndrome, celiac disease,
5 ulcerative colitis, stomach ulcers, diverticulitis, pouchitis, proctitis or chronic diarrhea.

15. The method of Claim 8, wherein said angiotensin converting enzyme inhibitor is selected from the group consisting of alacepril, benazepril (Lotensin), captopril (Capoten), cilazapril, ceranapril, delapril, enalapril (Vasotec), enalaprilat, fosinopril (Monopril),
10 fosinoprilat, imidapril, lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), perindoprilat, quinapril (Accupril), quinaprilat, ramipril (Altace), saralasin acetate, spirapril, temocapril,trandolapril (Mavik), Bioproject BP1.137, Chiesi CHF 1514, Fisons FPL-66564, idrapril, Marion Merrell Dow MDL-100240, and Servier S-5590.

15 16. A pharmaceutical preparation comprising: an ACE inhibitor and a second compound capable of reducing a symptom of inflammatory bowel disease or short bowel syndrome.

17. The pharmaceutical preparation of Claim 16, further comprising instructions for
20 using said preparation for the treatment of inflammatory bowel disease.